Does statin therapy provide mortality benefit in people living with HIV?

  • Uthman OA & al.
  • BMC Infect Dis
  • 5 Jun 2018

  • from Sarfaroj Khan
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This meta-analysis suggests that statin use may confer moderate mortality benefit in people living with HIV.

Why this matters

  • Dyslipidaemias are the most common cardiometabolic disorders that affect people with HIV.
  • Although studies of statins in HIV have evaluated subclinical cardiovascular disease (CVD), none has evaluated associations between statin use and hard CVD endpoints.

Study design

  • Systematic review and meta-analysis of 7 studies including 35,708 participants with HIV from inception up to April 2018.
  • Funding: None disclosed.

Key results

  • Overall, percentage of participants receiving statin therapy was between 8% and 35% and the percentage of participants with hypertension was between 14% and 35%.
  • 33% reduced risk was seen among patients receiving statin therapy (HR, 0.67; 95% CI, 0.39-0.96).
  • In the sensitivity analyses after removing the lower quality studies, the pooled HR from the 2 weighting schemes were 0.82 (95% CI, 0.49-1.35) and 0.76 (95% CI, 0.50-1.13), respectively, for mortality risk after statin use.
  • Mortality rate due to cardiovascular disease was reported by 2 studies (pooled HR, 0.69; 95% CI, 0.37-1.62).

Limitations

  • Observational studies were included.
  • Risk for bias.